ImmunityBio Q3 revenue rises 53% to $48.7 million; net loss widens to $184.6 million
ImmunityBio reported third-quarter 2026 net product revenue of $48.7 million, up 53% from a year earlier, and nine-month net product revenue of $143.6 million, up 92%. Net loss attributable to common stockholders rose to $184.6 million for the quarter from $67.3 million, mainly due to non-cash fair value changes in a related-party convertible note, warrant and derivative liabilities after a higher common stock price, along with higher interest expense and operating costs.
Key points
- Q3 2026 net product revenue was $48.7 million, up 53% year-over-year; nine-month net product revenue was $143.6 million, up 92%.
- Q3 2026 net loss attributable to common stockholders was $184.6 million, versus $67.3 million in Q3 2025; basic loss per share was $0.17 versus $0.07.
- Nine-month net loss attributable to common stockholders was $1.0 billion, versus $289.5 million a year earlier.
- Cash, cash equivalents and marketable securities totaled $334.3 million as of September 30, 2026.
The filing
Written by AI on Nov 9, 2026, 7:45 AM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.